论文部分内容阅读
目的观察对阿德福韦酯治疗慢性乙型肝炎肝纤维化的疗效,进行临床效果分析。方法将180例慢性乙型肝炎肝纤维化患者随机分为两组:对照组给予保肝、利胆等内科综合治疗,治疗组在上述基础上加用阿德福韦酯10mg/d,口服,两组疗程均为48周。结果阿德福韦酯组临床疗效及肝纤维化指标改善情况均优于对照组,治疗组有效率91.3%;DNA阴转率73.9%;对照组有效率66.7%;DNA阴转率4.8%。两组比较差异有统计学意义(P<0.05),未出现严重不良反应。结论阿德福韦酯能明显提高慢性乙型肝炎肝纤维化的治疗效果,安全性良好。
Objective To observe the curative effect of adefovir dipivoxil on chronic hepatitis B with hepatic fibrosis and analyze its clinical effect. Methods 180 patients with chronic hepatitis B liver fibrosis were randomly divided into two groups: control group given liver protection, gallbladder and other medical comprehensive treatment, the treatment group based on the above plus adefovir dipivoxil 10mg / d, oral, The two groups were treated for 48 weeks. Results Adefovir dipivoxil group had better clinical curative effect and liver fibrosis index than the control group. The effective rate was 91.3% in the treatment group, 73.9% in the DNA negative conversion rate, 66.7% in the control group and 4.8% in the DNA negative conversion rate. The difference between the two groups was statistically significant (P <0.05), no serious adverse reactions. Conclusion Adefovir dipivoxil can significantly improve the therapeutic effect of chronic hepatitis B with liver fibrosis, and its safety is good.